Table 1.
Patient and Clinical Characteristics – All Patients and by Recipient CMV Serostatus
| Measure | All (N=613) | R+ (N=529) | R− (N=84) |
|---|---|---|---|
| Diagnosis | |||
| AML | 464 (76) | 413 (78) | 51 (61) |
| MDS | 149 (24) | 116 (22) | 33 (39) |
| HLA DPB1 matching status, n (%) | |||
| Yes | 363 (59) | 309 (58) | 54 (64) |
| No | 250 (41) | 220 (42) | 30 (36) |
| HLA DPB1 mismatching direction, n (%) | |||
| GvH | 37 (15) | 29 (13) | 8 (27) |
| HvG | 17 (7) | 13 (6) | 4 (13) |
| Both | 196 (78) | 178 (81) | 18 (60) |
| Gender, n (%) | |||
| Male | 346 (56) | 293 (55) | 53 (63) |
| Female | 267 (44) | 236 (45) | 31 (37) |
| Age at allo-SCT (years) | |||
| Mean | 53.0 | 52.6 | 55.4 |
| Standard deviation | 12.4 | 12.4 | 11.8 |
| Median | 55.6 | 55.2 | 57.2 |
| Minimum, Maximum | 19.6, 77.0 | 19.6, 74.4 | 20.5, 77.0 |
| Race/Ethnicity, n (%) | |||
| White | 495 (81) | 415 (78) | 80 (95) |
| Hispanic | 69 (11) | 67 (13) | 2 (2) |
| Black | 21 (3) | 20 (4) | 1 (1) |
| Asian | 12 (2) | 12 (2) | 0 |
| Other | 1 (0.2) | 1 (0.2) | 0 |
| Unknown | 15 (2) | 14 (3) | 1 (1) |
| Transplant type, n (%) | |||
| MRD | 297 (48) | 255 (48) | 42 (50) |
| MUD | 316 (52) | 274 (52) | 42 (50) |
| Conditioning regimen, n (%) | |||
| Myeloablative | 497 (81) | 430 (81) | 67 (80) |
| Non myeloablative | 116 (19) | 99 (19) | 17 (20) |
| Conditioning regimen type, n (%) | |||
| Fludarabine+Busulfan+/−ATG | 376 (61) | 321 (61) | 55 (65) |
| Fludarabine+Melphalan+/−ATG | 83 (14) | 71 (13) | 12 (14) |
| Other | 154 (25) | 137 (26) | 17 (20) |
| In vivo T-cell depletion (ATG) | |||
| Yes | 313 (51) | 273 (52) | 40 (48) |
| No | 300 (49) | 256 (48) | 44 (52) |
| CMV risk groups, n (%) | |||
| D+/R+ | 269 (44) | 269 (51) | 0 |
| D−/R− | 50 (8) | 0 | 50 (60) |
| D+/R− | 34 (6) | 0 | 34 (40) |
| D−/R+ | 260 (42) | 260 (49) | 0 |
| Transplant cell source, n (%) | |||
| PBMC | 432 (70) | 369 (70) | 63 (75) |
| Marrow | 181 (30) | 160 (30) | 21 (25) |
| Transplant year, n (%) | |||
| 2005–2008 | 285 (46) | 242 (46) | 43 (51) |
| 2009–2011 | 328 (54) | 287 (54) | 41 (49) |
| Disease risk, n (%) | |||
| Low | 34 (6) | 29 (6) | 5 (6) |
| Int | 175 (29) | 155 (29) | 20 (24) |
| Int-1 | 45 (7) | 33 (6) | 12 (14) |
| Int-2 | 52 (9) | 41 (8) | 11 (13) |
| High | 304 (50) | 268 (51) | 36 (43) |
| Disease status at transplant, n (%) | |||
| Complete response | 333 (54) | 294 (56) | 39 (46) |
| Refractory | 205 (33) | 178 (34) | 27 (32) |
| Untreated | 73 (12) | 56 (11) | 17 (20) |
| Not evaluated | 1 (0.2) | 0 | 1 (1) |
| Unknown | 1 (0.2) | 1 (0.2) | 0 |
| GVHD prophylaxis, n (%) | |||
| Methotrexate+Tacrolimus | 562 (92) | 490 (93) | 72 (86) |
| Methotrexate+Tacrolimus+Others | 0 | 0 | 0 |
| MMF+Tacrolimus | 3 (0.5) | 2 (0.4) | 1 (1) |
| Other | 47 (8) | 37 (7) | 10 (12) |
| None | 1 (0.2) | 0 | 1 (1) |
Abbreviations: R+ = CMV seropositive Recipient; R- = CMV seronegative Recipient; AML = Acute Myelogenous Leukemia; MDS = Myelodysplastic Syndrome; GvH = Graft vs. Host; HvG = Host vs. Graft; MRD = Matched Related Donor; MUD = Matched Unrelated Donor; D = Donor; R = Recipient; PBMC = Peripheral Blood Mononuclear Cells.